Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE005782 |
ID: | TCMBANKHE005782 |
药用植物名: | 小唐松草 |
TCM_ID_id: | 3226 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000623 | thalfoetidine | C38H42N2O7 | 638.75 | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C4)O)OC5=CC=C(CC6C7=CC(=C(C(=C7CCN6C)O3)OC)OC)C=C5)OC)OC | |
| TCMBANKIN000737 | isothalisopavine | C20H23NO4 | 341.4 g/mol | CN1CC2C3=CC(=C(C=C3C1CC4=C2C(=C(C=C4)OC)O)OC)OC | |
| TCMBANKIN001315 | thalisopynine | ||||
| TCMBANKIN001524 | thalmelatine | C40H46N2O8 | 682.8 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC5=CC(=C(C=C5CC6C7=CC(=C(C=C7CCN6C)OC)O)OC)OC)OC)OC | |
| TCMBANKIN003103 | przewalstidine | C42H50N2O10 | 742.9 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=CC(=C5OC)CC6C7=CC(=C(C(=C7CCN6C)O)OC)OC)OC | |
| TCMBANKIN005661 | faurine | C29H33NO7 | 507.6 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)OC)OC)OC5=CC(=C(C=C5CO)OC)OC)OC | |
| TCMBANKIN006064 | przewalstinine | C42H50N2O9 | 726.9 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=C(C(=C5)CC6C7=CC(=C(C=C7CCN6C)OC)OC)OC)OC | |
| TCMBANKIN006271 | pennsylvanamine | C39H44N2O8 | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC5=CC(=C(C=C5CC6C7=CC(=C(C=C7CCN6C)OC)OC)O)OC)O)OC | ||
| TCMBANKIN007158 | neothalfine | C38H36N2O8 | CN1CCC2=C3C(=C(C=C2C1CC4=CC(=C(C=C4)OC)OC5=CC=C(CC6=NC=CC7=C6C(=C(C8=C7OCO8)OC)O3)C=C5)OC)OC | ||
| TCMBANKIN008902 | Thalrugosidine | thalrugosidine; THALRUGOSIDINE; 33954-34-6; CHEMBL507858 | C38H42N2O7 | 638.75 | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C4)OC)OC5=CC=C(CC6C7=CC(=C(C(=C7CCN6C)O3)OC)OC)C=C5)O)OC |
| TCMBANKIN009094 | przewalstidinine | C42H50N2O10 | 742.9 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=C(C(=C5)CC6C7=CC(=C(C(=C7CCN6C)O)OC)OC)OC)OC | |
| TCMBANKIN009096 | (+)-preocoteine | C21H25NO5 | CN1CCC2=C(C(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC)O)OC)OC | ||
| TCMBANKIN012605 | 3-methoxyfaurithaline | C40H46N2O9 | 698.8 g/mol | CN1CCC2=C3C1CC4=C(C3=C(C(=C2OC)OC)OC)C(=C(C=C4OC5=C(C=CC(=C5)CC6C7=CC(=C(C=C7CCN6C)OC)O)OC)OC)O | |
| TCMBANKIN013820 | thaliracebine | thaliracebine | C39H44N2O7 | 652.8 g/mol | CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC4=CC=C(C=C4)CC5C6=CC7=C(C(=C6CCN5C)OC)OCO7)OC)OC |
| TCMBANKIN014183 | munitagine | C19H21NO4 | 327.4 g/mol | CN1C2CC3=C(C1CC4=CC(=C(C=C24)O)OC)C(=C(C=C3)OC)O | |
| TCMBANKIN014196 | przewalskinine | C42H48N2O10 | 740.8 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=C(C(=C5)CC6C7=CC(=C8C(=C7CCN6C)OCO8)OC)OC)OC | |
| TCMBANKIN014718 | (+)-N-methylnantenine | C21H24NO4+ | C[N+]1(CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC)C | ||
| TCMBANKIN014914 | thalidezine | thalifarazine; AK687395; AKOS032946265; Thalidesine; ZINC139836561 | C38H42N2O7 | 638.75 | CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(CCN6C)C(=C(C(=C7O3)OC)OC)O)OC)OC |
| TCMBANKIN016503 | eschscholtzidine | C20H21NO4 | 339.4 g/mol | CN1C2CC3=CC4=C(C=C3C1CC5=CC(=C(C=C25)OC)OC)OCO4 | |
| TCMBANKIN017827 | thaliadine | C30H33NO8 | 535.6 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=CC(=C(C=C5C=O)OC)OC | |
| TCMBANKIN018472 | (-)-argemonine | C21H25NO4 | 355.4 g/mol | CN1C2CC3=CC(=C(C=C3C1CC4=CC(=C(C=C24)OC)OC)OC)OC | |
| TCMBANKIN018858 | thalisamine | C38H42N2O7 | CN1CCC2=C3C1CC4=CC(=C(C=C4)OC)OC5=CC=C(CC6C7=CC(=C(C=C7CCN6)OC)OC3=C(C(=C2OC)OC)OC)C=C5 | ||
| TCMBANKIN019053 | thalirabine | thalirabine | C40H47N2O8+ | 683.8 g/mol | CN1CCC2=C(C3=C(C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=CC(=C(C(=C7CC[N+]6(C)C)O)OC)OC)OC)OCO3)OC |
| TCMBANKIN019251 | preocoteine N-oxide | C21H25NO6 | 387.4 g/mol | C[N+]1(CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)O)OC)OC)[O-] | |
| TCMBANKIN021092 | O-methylthalisopavine | C21H25NO4 | CN1CC2C3=CC(=C(C=C3CC1C4=CC(=C(C=C24)OC)OC)OC)OC | ||
| TCMBANKIN021240 | thalisopavine | C20H23NO4 | 341.4 g/mol | CN1CC2C3=CC(=C(C=C3CC1C4=CC(=C(C=C24)OC)OC)O)OC | |
| TCMBANKIN021419 | thamnolic acid | thamnolicacid | C19H16O11 | 420.3 g/mol | CC1=CC(=C(C(=C1C(=O)OC2=C(C(=C(C(=C2C)C(=O)O)O)C=O)O)O)C(=O)O)OC |
| TCMBANKIN021769 | O-methylfaurine | C30H35NO7 | 521.6 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)OC)OC)OC5=CC(=C(C=C5COC)OC)OC)OC | |
| TCMBANKIN024268 | faurithaline | C39H44N2O8 | 668.8 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4OC5=C(C=CC(=C5)CC6C7=CC(=C(C=C7CCN6C)OC)O)OC)OC)O)OC)OC | |
| TCMBANKIN025349 | dehydrothalmelatine | ||||
| TCMBANKIN025727 | przewaline | C41H42N2O10 | 722.8 g/mol | CN1CCC2=C3C(=C(C=C2C1CC4=C(C(=C(C=C4)OC)OC5=C(C=C6C(=C5OC)CC7=NC=CC8=CC(=C(C6=C78)OC)OC)OC)OC)OC)OCO3 | |
| TCMBANKIN027370 | przewalidine | C20H24NO4+ | 342.4 g/mol | C[N+]1(CC2C3=C(CC1C4=CC(=C(C=C24)OC)O)C(=C(C=C3)OC)O)C | |
| TCMBANKIN030788 | 8-hydroxypseudocoplisine | ||||
| TCMBANKIN031829 | thalactamine | C13H15NO4 | 249.26 g/mol | CN1C=CC2=C(C(=C(C=C2C1=O)OC)OC)OC | |
| TCMBANKIN033734 | halipetalmine | ||||
| TCMBANKIN034967 | przewalskine | C42H48N2O10 | 740.8 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=CC(=C5OC)CC6C7=CC(=C8C(=C7CCN6C)OCO8)OC)OC | |
| TCMBANKIN035203 | thalictrogamine | C39H44N2O8 | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC5=CC(=C(C=C5CC6C7=CC(=C(C=C7CCN6C)OC)O)OC)OC)O)OC | ||
| TCMBANKIN035844 | fauridine | C40H46N2O8 | 682.8 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)OC)OC)OC5=CC(=C(C=C5CC6C7=CC(=C(C=C7CCN6C)OC)O)OC)OC)OC | |
| TCMBANKIN036002 | przewalstine | C42H50N2O9 | 726.9 g/mol | CN1CCC2=C3C1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=CC(=C5OC)CC6C7=CC(=C(C=C7CCN6C)OC)OC)OC | |
| TCMBANKIN036167 | foetidine | C47H49N5O9 | CCC(C1=C(C(=O)N2CC3=CC4=CC=CC=C4N=C3C2=C1)COC(=O)C)(C(=O)OC5=CC=C(C=C5)C=CC(=O)NCCCNCCCCNC(=O)C=CC6=CC=C(C=C6)O)O | ||
| TCMBANKIN046635 | 5-hydroxy-1-(3,4-dihydroxy-5-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)heptan-3-one | C21H26O7 | 390.4 g/mol | COC1=CC(=CC(=C1O)O)CCC(=O)CC(CCC2=CC(=C(C=C2)O)OC)O | |
| TCMBANKIN058114 | trans-caffeic acid | 3-(3,4-dihydroxy-phenyl)-acrylic acid; caffeic acid; Caffeate; Lopac-C-0625; 71693-97-5; DivK1c_006624; KBio2_007302; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NCGC00015206-02; CAS-3331-39-5; 60020_FLUKA; AI3-63211; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC623438; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; KBio2_004734; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; CHEMBL1320034; AIDS-002287; AIDS002287; 501-16-6; CHEBI:36281; Prestwick1_000902; KBio1_001568; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; AKOS000273846; OR1165; SMR000058214; Spectrum2_001612; 3,4-dihydroxycinnamate; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; KOP; AC1NO658; CCRIS 847; Caffeic acid dehydrogenation homopolymer; SPECTRUM1503987; Spectrum4_001694; SCHEMBL3682144; NCGC00017364-01; NCGC00022654-08; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; 78734C5A-1281-44D4-B8A0-A3188AD437E3; cis-Caffeic acid; 3-(3,4-dihydroxyphenyl)acrylic acid; Cinnamic acid, 3,4-dihydroxy-; KBioGR_001988; 3,4-Dihydroxybenzeneacrylic acid; 3,4-dihydroxycinnamic acid; trans-caffeic acid; AIDS-026339; NCGC00015206-01; HSDB 7088; ZINC4482687; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-dihydroxyphenyl)prop-2-enoate; Isocaffeic acid; SBB006475; InChI=1/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2; NCGC00017364-02; EU-0100208; C01197; MolPort-001-759-162; KBioSS_002166; Caffeic acid pure; caffeic acid ; trans-Caffeate; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; NSC 57197; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; Spectrum_001686; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; KBio2_002166; Caffeic acid, cis-; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3,4-Dihydroxybenzeneacrylate; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; 4361-87-9; 3,4-Dihydroxy-trans-cinnamate; caffeicacid; AR-360/40806927; EINECS 206-361-2; 60018_FLUKA; Caffeic acid polymer; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; NCGC00022654-04; ZX-AL002121; C0625_SIGMA; SDCCGMLS-0002982.P003; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; SPBio_001643; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); NCGC00017364-03; 3-(3,4-dihydroxyphenyl)prop-2-enoic acid; AC1LU7RL; SPBio_002943; CHEBI:16433; AIDS026339; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; CHEBI:17395; TNP00311; SpecPlus_000528; Prestwick0_000902; MLS000069738; 3,4-dihydroxy-cinnamic acid; 3-(3,4-Dihydroxyphenyl)propenoic acid; NCI60_004400; NSC57197; Caffeic; Lopac-C-0625; NCGC00015206-01; Caffeic acid; cis-Caffeic acid; NCGC00017364-01; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; C01481; 331-39-5; NCGC00015206-02; CAS-3331-39-5; 3,4-Dihydroxycinnamic acid; CHEBI:17395; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; TNP00311; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeate; 1- coffee acid | C9H8O4 | 180.16 g/mol | C1=CC(=C(C=C1C=CC(=O)O)O)O |
| TCMBANKIN058454 | glaunine | guanine (1,7-dihydro-form) | C5H5N5O | C1=NC2=C(N1)C(=O)N=C(N2)N | |
| TCMBANKIN059505 | evodin | C26H30O8 | 470.5 g/mol | CC1(C2CC(=O)C3(C(C24COC(=O)CC4O1)CCC5(C36C(O6)C(=O)OC5C7=COC=C7)C)C)C | |
| TCMBANKIN061300 | (-)-argemonine | C21H25NO4 | 355.4 g/mol | CN1C2CC3=CC(=C(C=C3C1CC4=CC(=C(C=C24)OC)OC)OC)OC | |
| TCMBANKIN061319 | thalfinine | C39H42N2O8 | 666.8 g/mol | CN1CCC2=C3C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=CC(=C(C(=C7CCN6C)OC3=C8C(=C2OC)OCO8)OC)OC)OC | |
| TCMBANKIN061335 | TBL;thalicarpine | NSC 68075; Thalicarpin; NSC-68075; 6a.alpha.-Aporphine, 9-[[4,5-dimethoxy-.alpha.-((S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2,10-trimethoxy-; 4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-9-(4,5-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-1,2,10-trimethoxy-6-methyl-; AIDS-002681; NY IV34 1; 4H-Dibenzo(de,g)quinoline, 9-(4,5-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (S-(R*,R*))-; 4H-Dibenzo[de,g]quinoline, 9-[4,5-dimethoxy-2-[[(1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (6aS)-; Taliblastine; (6aS)-9-(2-{[(1S)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-4,5-dimethoxyphenoxy)-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline; C09655; STOCK1N-51856; 6aalpha-Aporphine, 9-((4,5-dimethoxy-alpha-(1beta,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl)oxy)-1,2,10-trimethoxy- (8CI); AIDS002681; NSC68075; NCI60_028786; (6aS)-9-(2-{[(1S)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-4,5-dimethoxyphenoxy)-1,2,10-trimethoxyaporphine; 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-1,2,10-trimethoxy-6-methyl-; Thalicarpine; Taliblastin; NY IV-34-1; NY-IV-34-1; 4H-Dibenzo(de,g)quinoline, 9-(4,5-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (S-(R*,R*))- (9CI); 4H-Dibenzo[de,g]quinoline, 9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, [S-(R*,R*)]-; En 125-214; Thaliblastine; CHEBI:9509; 5373-42-2; 6a.alpha.-Aporphine, 9-[[4,5-dimethoxy-.alpha.-(1.beta.,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2,10-trimethoxy- | C41H48N2O8 | 696.83 | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC5=CC(=C(C=C5CC6C7=CC(=C(C=C7CCN6C)OC)OC)OC)OC)OC)OC |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab